Eilean Therapeutics announced the advancement of ZE74-0282 into first-in-human clinical development. ZE74-0282 is a novel, highly selective inhibitor of the mutated Janus kinase 2 (JAK2) V617F variant ...
Self-awareness—the ability to understand your emotional triggers, cognitive patterns and motivations—is the ultimate career ...
This cloud will be an national talent architecture linking schools, universities, research institutions, start-ups, PSUs and ...
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, ...
AgingIN invites elder care leaders to the ReImagining Care Models conference for dynamic discussions on person-directed ...
High-profile incidents, different industries. An unmistakable pattern: GenAI hallucinations are enterprise liabilities, ...
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI ...
Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...
A rise in reports of psychosis-like symptoms is increasing pressure on companies and policymakers to address the potential ...
BGB-B2033, a bispecific antibody, targets 4-1BB and GPC3, showing potential in advanced hepatocellular carcinoma (HCC) ...
The Blazpay AI crypto presale has just cleared a major credibility milestone: a full smart contract audit that validates the ...
Topline final safety and efficacy results for the full 36 weeks of treatment from all participants will be available in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback